EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

EI

259.5

-1.48%↓

SAN

84.4

-1.16%↓

MRK1

108.7

+0.83%↑

SHL.DE

47.28

0%↓

ARGX

603.4

+0.2%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

58.1 -0.34

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.75

Máximo

58.6

Indicadores-chave

By Trading Economics

Rendimento

3.9M

27M

Vendas

4.8M

160M

P/E

Médio do Setor

22.51

35.724

EPS

0.423

Rendimento de Dividendos

1.62

Margem de lucro

16.767

Funcionários

2,188

EBITDA

4.2M

35M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+38.56% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

161M

3B

Abertura anterior

58.44

Fecho anterior

58.1

Sentimento de Notícias

By Acuity

7%

93%

5 / 372 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de ago. de 2025, 18:43 UTC

Grandes Movimentos do Mercado

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 de ago. de 2025, 15:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29 de ago. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

29 de ago. de 2025, 20:24 UTC

Ganhos

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 de ago. de 2025, 20:17 UTC

Ganhos

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 de ago. de 2025, 19:18 UTC

Conversa de Mercado

Oil Futures End Week With Modest Gains -- Market Talk

29 de ago. de 2025, 18:59 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 de ago. de 2025, 18:36 UTC

Ganhos

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 de ago. de 2025, 18:26 UTC

Ganhos

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 de ago. de 2025, 17:48 UTC

Conversa de Mercado

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 de ago. de 2025, 17:10 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 de ago. de 2025, 16:57 UTC

Ganhos

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 de ago. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 de ago. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 de ago. de 2025, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 de ago. de 2025, 16:26 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 de ago. de 2025, 16:25 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 de ago. de 2025, 16:24 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Adjusts Offer for Banco de Sabadell

29 de ago. de 2025, 16:23 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 de ago. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

29 de ago. de 2025, 16:06 UTC

Conversa de Mercado

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 de ago. de 2025, 15:12 UTC

Conversa de Mercado
Ganhos

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 de ago. de 2025, 15:09 UTC

Ganhos

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 de ago. de 2025, 15:01 UTC

Conversa de Mercado

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 de ago. de 2025, 14:49 UTC

Ganhos

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 de ago. de 2025, 14:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 de ago. de 2025, 14:49 UTC

Conversa de Mercado

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 de ago. de 2025, 14:48 UTC

Ganhos

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 de ago. de 2025, 14:43 UTC

Conversa de Mercado

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29 de ago. de 2025, 14:38 UTC

Conversa de Mercado

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

38.56% parte superior

Previsão para 12 meses

Média 80.85 EUR  38.56%

Máximo 90 EUR

Mínimo 71.7 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

5 / 372 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.